

Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis

Antonella Nai,^{1,2} Mariateresa Pettinato,^{1,2} Giorgia Federico,³ Violante Olivari,¹ Francesca Carlomagno^{3} and Laura Silvestri^{1,2*}*

**Contributed equally as co-senior authors*

¹Division of Genetics and Cell Biology, Ospedale San Raffaele, Milan; ²Vita-Salute San Raffaele University, Milan and ³Department of Molecular Medicine and Medicine Biotechnology (DMMBM), University of Naples Federico II, Institute of Endocrinology and Experimental Oncology (IEOS), CNR, Naples, Italy

*Correspondence: FRANCESCA CARLOMAGNO - francesca.carlomagno@unina.it
LAURA SILVESTRI - silvestri.laura@hsr.it*

doi:10.3324/haematol.2019.224857

Supplemental Table. Hematological parameters in untreated and tamoxifen-treated C57BL/6.

days post Tamoxifen	0	4	11
RBCs (10⁶/ul)	12.2 ± 1.2	10.4 ± 0.5*	10.4 ± 0.9*
Hb (g/dL)	18.2 ± 1.09	16.2 ± 0.8*	16.0 ± 1.2*
Hct (%)	58.6 ± 3.4	52.2 ± 3.0*	52.0 ± 5.1
MCV (fL)	48.3 ± 2.5	50.0 ± 3.3	50.2 ± 2.2
MCH (pg)	15.0 ± 0.8	15.5 ± 1.1	15.4 ± 1.0

*: P<.05; treated vs untreated.